| Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. | |
| | |
MedLine Citation:
|
PMID: 20053692 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters. METHODS: HIV-infected patients with plasma viral load <400 copies/mL, fasted triglycerides from 2.3 to 11.4 mmol/L and/or fasted low-density lipoprotein (LDL)-cholesterol >4.1 mmol/L were randomized to switch the nucleoside reverse transcriptase inhibitor (NRTI) backbone to fixed-dose combination tenofovir disoproxil fumarate + emtricitabine or to maintain the baseline antiretroviral regimen (the control group). The study has been registered with ClinicalTrials.gov under the identifier NCT00323492. RESULTS: Ninety-one patients were included in the intent-to-treat (ITT) analysis with triglycerides 2.4 mmol/L and LDL-cholesterol 4.0 mmol/L (median values). At week 12, the median changes from baseline of triglycerides were -0.5 mmol/L (-25%; n = 46) and -0.1 mmol/L (-6%; n = 45) in the tenofovir disoproxil fumarate + emtricitabine and control groups, respectively, indicating a difference of -0.4 mmol/L (P = 0.034) [95% confidence interval (CI): -0.9 to -0.0]. Similarly for LDL-cholesterol, changes of -0.4 mmol/L (-9%) and -0.1 mmol/L (-1%) were observed in the tenofovir disoproxil fumarate + emtricitabine and control groups, respectively, indicating a difference of -0.4 mmol/L (P = 0.031) [95% CI: -0.7 to -0.0]. The proportion of patients with LDL-cholesterol >4.1 mmol/L decreased from 48% at baseline to 26% at week 12 in the tenofovir disoproxil fumarate + emtricitabine group versus no change in the control group. No virological failure was observed during the study. CONCLUSIONS: Switching to tenofovir disoproxil fumarate + emtricitabine in dyslipidaemic HIV-infected patients improves triglycerides and LDL-cholesterol. |
| | |
Authors:
|
M A Valantin; R Bittar; P de Truchis; D Bollens; L Slama; P Giral; D Bonnefont-Rousselot; P P?tour; C Aubron-Olivier; D Costagliola; C Katlama; |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-01-06 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: 65 ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-10 Completed Date: 2010-04-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: England |
Other Details:
|
Languages: eng Pagination: 556-61 Citation Subset: IM |
Affiliation:
|
Department of Infectious Diseases, AP-HP, Piti?-Salp?tri?re Hospital, Paris, France. marc-antoine.valantin@psl.ap-hop-paris.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenine
/
adverse effects,
analogs & derivatives*,
therapeutic use Adult Anti-HIV Agents / adverse effects, therapeutic use* Cholesterol, LDL / blood* Deoxycytidine / adverse effects, analogs & derivatives*, therapeutic use Female HIV Infections / drug therapy* Humans Male Middle Aged Nucleosides / adverse effects, therapeutic use* Phosphonic Acids / adverse effects, therapeutic use* Triglycerides / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/Cholesterol, LDL; 0/Nucleosides; 0/Phosphonic Acids; 0/Triglycerides; 0/emtricitabine; 0/tenofovir disoproxil; 73-24-5/Adenine; 951-77-9/Deoxycytidine |
| Investigator | |
Investigator/Affiliation:
|
M Bentata / ; F Rouges / ; F Touam / ; J F Bergmann / ; A Rami / ; M Parrinello / ; Z Ouazene / ; B Lef?bvre / ; O Bouchaud / ; T Huynh / ; O Caubet / ; J L Pellegrin / ; L De Saint Martin / ; V Bellein / ; M L Guenegues / ; J F Delfraissy / ; P Dellamonica / ; J Durant / ; M A Serini / ; C Drobacheff-Thi?baut / ; A Foltzer / ; J A Gastaut / ; E Peyrouse / ; B Hoen / ; A Foltzer / ; V Jeantils / ; S Tassi / ; L Schneider / ; N Bentaleb / ; C Perronne / ; H Berth? / ; G Pialoux / ; C Fontaine / ; L Piroth / ; S Treuvelot / ; T Prazuck / ; L Hocqueloux / ; B De Dieuleveult / ; D Sereni / ; C Pintado / ; J M Ragnaud / ; D Neau / ; I Raymond / ; A Simon / ; C Trepo / ; B Lebouch? / ; C Brochier / ; R Verdon / ; J J Parienti / ; P Feret / ; B Bonnet / ; M Doucet / ; R Ebrahimi / ; A Firek / ; J Gonzalez / ; A Trylesinski / ; F Beauvais / ; V H?rault / ; T Caraes / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Molecular characterization of extended-spectrum {beta}-lactamases in clinical Escherichia coli and K...
Next Document: Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantat...